Agilent Technologies, Inc. (A)

Agilent Technologies' stock has experienced various events and movements in the past six months. As of May 4, 2026, the share price was $112.18, representing an increase of 3.52% over the past year, but the year-to-date total return for A stock is down 14.68%. Key corporate events included naming Michael Buckner as Chief Legal Officer, the announcement of the second-quarter fiscal year 2026 financial results release date, resolution of litigation between Axion BioSystems and Agilent Technologies, showcasing cancer research solutions at AACR 2026, the 2026 Annual General Meeting, participation in TD Cowen's 46th Annual Health Care Conference, the Q1 2026 Earnings Conference Call, and presenting at the 44th Annual J.P. Morgan Healthcare Conference. Agilent concluded its fiscal year 2025 with strong operational results, reporting revenue of $1.86 billion for the fourth quarter ended October 31, 2025.

While Agilent Technologies' revenue and earnings forecasts often incorporate expected seasonality in its markets, the actual experience of seasonality can vary due to customer spending policies and longer sales cycles. Agilent has intentionally built a significant portion of its revenue stream from services and consumables, which are tied to its installed base rather than new instrument placements. This makes the Agilent CrossLab business counter-cyclical, as demand for services, compliance support, and replacement parts can increase when customers defer capital equipment purchases.

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets, providing instruments, software, services, and consumables for laboratories worldwide. The company operates primarily within the healthcare equipment and services industry and is organized into three main segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Agilent offers solutions in areas such as automation, bioreagents, gas and liquid chromatography, mass spectrometry, spectroscopy, informatics, microarrays, and vacuum technologies. The Diagnostics and Genomics segment provides pathology products, specific proteins, flow cytometry reagents, companion diagnostics, and cytogenetic research solutions. Agilent also provides lab management services, including enterprise asset management, equipment management, software maintenance, and regulatory compliance.

Agilent Technologies has a significant global presence, serving customers in 110 countries with approximately 18,000 employees worldwide. The company maintains sales offices, logistics centers, and business facilities across three major geographies, with its global headquarters in Santa Clara, California. Agilent operates subsidiaries in 31 countries, with a notable concentration in the United States, Mexico, and Japan. In fiscal year 2024, the Americas region was the largest contributor to revenue, followed by Asia Pacific, and Europe.

Agilent Technologies is recognized as a global leader in life sciences, diagnostics, and applied markets, known for its uncompromising integrity. The company is considered the premier laboratory partner for a better world. Agilent's brand reputation is built on its innovation engine and cost control efforts, which have led to strong growth and margin expansion. The company has a strong market share in the Laboratory Supply Wholesaling industry in the US. Agilent has received a consensus rating of "Buy" from analysts. No specific negative events significantly impacting Agilent Technologies' brand reputation in the past year were found.

Agilent Technologies' ownership is predominantly held by institutional investors. As of May 7, 2026, there were 1116 institutional owners and shareholders holding a total of 253,874,237 shares. Key institutional holders include Vanguard Group Inc., BlackRock, Inc., and Massachusetts Financial Services Co. Institutional investors hold over 91% of Agilent Technologies stock as of August 2025.